In Q1 FY2018 (ended June 30, 2018), Replimune reported no revenue and a net loss of $70.93 million, with an operating loss of $71.87 million. Diluted EPS was -$0.77. The company had no cash, equity, or long-term debt disclosed.
•Revenue was $0 for the quarter.
•Net loss of $70.93 million, a 6.9% increase year-over-year.
•Operating loss of $71.87 million, up 8.9% year-over-year.
•Diluted EPS of -$0.77, improving 2.5% year-over-year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Replimune Group, Inc., a clinical-stage biotechnology company focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4 RP3, which express immune-activating proteins that stimulate T cells. Founded in 2015, Replimune is headquartered in Woburn, Massachusetts.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies to treat cancer. Its proprietary product candidates are designed to activate the immune system against tumors. The lead candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, targeting a range of solid tumors. The company is also developing RP2, which expresses an anti-CTLA-4 antibody-like protein to block immune inhibition caused by CTLA-4, and RP3, which expresses immune-activating proteins that stimulate T cells. Replimune operates in the United States and the United Kingdom.
On which stock exchange is Replimune listed and what is its ticker symbol?
Replimune Group, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol REPL. The company's stock trades in US dollars (USD), reflecting its primary listing in the United States.
What sector and industry does Replimune operate in?
Replimune Group, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative oncolytic immunotherapies that leverage viruses to activate the immune system against cancer cells.
Where is Replimune headquartered and what markets does it serve?
Replimune Group, Inc. is headquartered in Woburn, Massachusetts, United States. The company serves markets in the United States and the United Kingdom, where it conducts its research and development activities for its oncolytic immunotherapy product candidates.
What are Replimune's main product candidates?
Replimune's lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, designed for a range of solid tumors. The company is also developing RP2, which expresses an anti-CTLA-4 antibody-like protein to block CTLA-4-mediated immune inhibition, and RP3, which expresses immune-activating proteins that stimulate T cells. All candidates are based on the company's proprietary oncolytic immunotherapy platform aimed at activating the immune system against cancer.